Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor

Human Gene Therapy

Volumn 16, Issue 3, 2005, Pages 328-338

  Jin, Hyun Tak ^a   Youn, Je In ^a   Kim, Hye Ju ^a   Lee, Jee Boung ^a   Ha, Sang Jun ^a   Jong, Sung Koh ^b   Sung, Young Chul ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LB 42908; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P40; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; INHIBITION KINETICS; LUNG METASTASIS; MEMORY CELL; MOUSE; NONHUMAN; PROTEIN SECRETION; PROVOCATION TEST; SURVIVAL RATE;

ADENOVIRIDAE; ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; FARNESYLTRANSTRANSFERASE; GENE THERAPY; GENETIC VECTORS; IMIDAZOLES; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; MICE; NEOPLASMS; NUCLEOPROTEINS; PIPERAZINES; PROTEIN SUBUNITS;

EID: 16344371747     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.328     Document Type: Article

References (53)

1. AMICI, A., SMORLESI, A., NOCE, G., SANTONI, G., CAPPELLETTI, P., CAPPARUCCIA, L., COPPARI, R., LUCCIARINI, R., PETRELLI, C., and PROVINCIALI, M. (2000). DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 7, 703-706.
2. ARMITAGE, J.O. (1998). Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92, 4491-4508.
3. BERD, D., and MASTRANGELO, M.J. (1988). Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 48, 1671-1675.
4. CHEN, L., CHEN, D., BLOCK, E., O'DONNELL, M., KUFE, D.W., and CLINTON, S.K. (1997). Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J. Immunol. 159, 351-359.
5. CHEN, S.A., TSAI, M.H., WU, F.T., HSIANG, A., CHEN, Y.L., LEI, H.Y., TZAI, T.S., LEUNG, H.W., JIN, Y.T., HSIEH, C.L., HWANG, L.H., and LAI, M.D. (2000). Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine. Clin. Cancer Res. 6, 4381-4388.
6. CLARKE, S., VOGEL, J.P., DESCHENES, R.J., and STOCK, J. (1988). Posttranslational modification of the Ha-ras oncogene protein: Evidence for a third class of protein carboxyl methyltransferases. Proc. Natl. Acad. Sci. U.S.A. 85, 4643-4647.
7. COLOMBO, M.P., and TRINCHIERI, G. (2002). Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 155-168.
8. COOPER, A.M., KIPNIS, A., TURNER, J., MAGRAM, J., FERRANTE, J., and ORME, I.M. (2002). Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J. Immunol. 168, 1322-1327.
9. COX, A.D., and DER, C.J. (2002). Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol. 2, 388-393.
10. D'ANDREA, A., CHANG, C., PHILLIPS, J.H., and LANIER, L.L. (1996). Regulation of T cell lymphokine production by killer cell inhibitory receptor recognition of self HLA class I alleles. J. Exp. Med. 184, 789-794.
11. DI CARLO, E., COMES, A., BASSO, S., DE AMBROSIS, A., MEAZZA, R., MUSIANI, P., MOELLING, K., ALBINI, A., and FERRINI, S. (2000). The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J. Immunol. 165, 3111-3118.
12. EHRKE, M.J., COHEN, S.A., and MIHICH, E. (1982). Selective effects of Adriamycin on murine host defense systems. Immunol. Rev. 65, 55-78.
13. GELDHOF, A.B., VAN GINDERACHTER, J.A., LIU, Y., NOEL, W., RAES, G., and DE BAETSELIER, P. (2002). Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood 100, 4049-4058.
14. GILLESSEN, S., CARVAJAL, D., LING, P., PODLASKI, F.J., STREMLO, D.L., FAMILLETTI, P.C., GUBLER, U., PRESKY, D.H., STERN, A.S., and GATELY, M.K. (1995). Mouse interleukin-12 (IL-12) p40 homodimer: A potent IL-12 antagonist. Eur. J. Immunol. 25, 200-206.
15. HA, S.J., LEE, C.H., LEE, S.B., KIM, C.M., JANG, K.L., SHIN, H.S., and SUNG, Y.C. (1999). A novel function of IL-12p40 as a chemotactic molecule for macrophages. J. Immunol. 163, 2902-2908.
16. HA, S.J., CHANG, J., SONG, M.K., SUH, Y.S., JIN, H.T., LEE, C.H., NAM, G.H., CHOI, G., CHOI, K.Y., LEE, S.H., KIM, W.B., and SUNG, Y.C. (2002). Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization. Nat. Biotechnol. 20, 381-386.
17. HENGST, J.C., MOKYR, M.B., and DRAY, S. (1980). Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res. 40, 2135-2141.
18. HOLSCHER, C., ATKINSON, R.A., ARENDSE, B., BROWN, N., MYBURGH, E., ALBER, G., and BROMBACHER, F. (2001). A protective and agonistic function of IL-12p40 in mycobacterial infection. J. Immunol. 167, 6957-6966.
19. HOON, D.S., FOSHAG, L.J., NIZZE, A.S., BOHMAN, R., and MORTON, D.L. (1990). Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res. 50, 5358-5364.
20. HORTON, H.M., DORIGO, O., HERNANDEZ, P., ANDERSON, D., BEREK, J.S., and PARKER, S.E. (1999). IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J. Immunol. 163, 6378-6385.
21. KAMINSKI, J.M., SUMMERS, J.B., WARD, M.B., HUBER, M.R., and MINEV, B. (2003). Immunotherapy and prostate cancer. Cancer Treat. Rev. 29, 199-209.
22. KELLY, J.M., DARCY, P.K., MARKBY, J.L., GODFREY, D.I., TAKEDA, K., YAGITA, H., and SMYTH, M.J. (2002). Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3, 83-90.
23. KLEIN, E., and MANTOVANI, A. (1993). Action of natural killer cells and macrophages in cancer. Curr. Opin. Immunol. 5, 714-718.
24. KOHL, N.E., OMER, C.A., CONNER, M.W., ANTHONY, N.J., DAVIDE, J.P., DESOLMS, S.J., GIULIANI, E.A., GOMEZ, R.P., GRAHAM, S.L., HAMILTON, K., et al. (1995). Inhibition of farnesyl-transferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1, 792-797.
25. LEE, S.W., CHO, J.H., and SUNG, Y.C. (1998). Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J. Virol. 72, 8430-8436.
26. LEE, S.W., YOUN, J.W., SEONG, B.L., and SUNG, Y.C. (1999). IL-6 induces long-term protective immunity against a lethal challenge of influenza virus. Vaccine 17, 490-496.
27. LEE, H., LEE, J., LEE, S., SHIN, Y., JUNG, W., KIM, J.H., PARK, K., KIM, K., CHO, H.S., RO, S., JEONG, S.W., CHOI, T., CHUNG, H.H., and KOH, J.S. (2001). A novel class of highly potent, selective, and non-peptidic inhibitor of Ras farnesyltransferase (FTase). Bioorg. Med. Chem. Lett. 11, 3069-3072.
28. LEE, J.Y., KIM, D.H., CHUNG, Y., SHIN, S.U., and KANG, C.Y. (2003). Comparison of the antitumor efficacies of Her-2/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice. Vaccine 21, 521-531.
29. LEHMANN, J., BELLMANN, S., WERNER, C., SCHRODER, R., SCHUTZE, N., and ALBER, G. (2001). IL-12p40-dependent agonistic effects on the development of protective innate and adaptive immunity against Salmonella enteritidis. J. Immunol. 167, 5304-5315.
30. MANGUES, R., CORRAL, T., KOHL, N.E., SYMMANS, W.F., LU, S., MALUMBRES, M., GIBBS, J.B., OLIFF, A., and PELLICER, A. (1998). Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 58, 1253-1259.
31. MARTH, T., STROBER, W., SEDER, R.A., and KELSALL, B.L. (1997). Regulation of transforming growth factor-beta production by interleukin-12. Eur. J. Immunol. 27, 1213-1220.
32. MATTNER, F., FISCHER, S., GUCKES, S., JIN, S., KAULEN, H., SCHMITT, E., RUDE, E., and GERMANN, T. (1993). The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur. J. Immunol. 23, 2202-2208.
33. MAZZEO, D., VIGANO, P., DI BLASIO, A.M., SINIGAGLIA, F., VIGNALI, M., and PANINA-BORDIGNON, P. (1998). Interleukin-12 and its free p40 subunit regulate immune recognition of endometrial cells: Potential role in endometriosis. J. Clin. Endocrinol. Metab. 83, 911-916.
34. MITCHELL, M.S. (2003). Combinations of anticancer drugs and immunotherapy. Cancer Immunol. Immunother. 52, 686-692.
35. MOCELLIN, S., ROSSI, C.R., LISE, M., and MARINCOLA, F.M. (2002). Adjuvant immunotherapy for solid tumors: From promise to clinical application. Cancer Immunol. Immunother. 51, 583-595.
36. PARDOLL, D.M. (1995). Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415.
37. POWER, C.A., GRAND, C.L., ISMAIL, N., PETERS, N.C., YURKOWSKI, D.P., and BRETSCHER, P.A. (1999). A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNgamma-producing T cells. J. Immunol. Methods 227, 99-107.
38. RAKHMILEVICH, A.L., TURNER, J., FORD, M.J., MCCABE, D., SUN, W.H., SONDEL, P.M., GROTA, K., and YANG, N.S. (1996). Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Natl. Acad. Sci. U.S.A. 93, 6291-6296.
39. REISS, Y., GOLDSTEIN, J.L., SEABRA, M.C., CASEY, P.J., and BROWN, M.S. (1990). Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62, 81-88.
40. ROVERO, S., AMICI, A., CARLO, E.D., BEI, R., NANNI, P., QUAGLINO, E., PORCEDDA, P., BOGGIO, K., SMORLESI, A., LOLLINI, P.L., LANDUZZI, L., COLOMBO, M.P., GIOVARELLI, M., MUSIANI, P., and FORNI, G. (2000). DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165, 5133-5142.
41. SAHASRABUDHE, D.M., DEKERNION, J.B., PONTES, J.E., RYAN, D.M., O'DONNELL, R.W., MARQUIS, D.M., MUDHOLKAR, G.S., and MCCUNE, C.S. (1986). Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Response Mod. 5, 581-594.
42. SCHULTZ, J., PAVLOVIC, J., STRACK, B., NAWRATH, M., and MOELLING, K. (1999). Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA. Hum. Gene Ther. 10, 407-417.
43. SHURIN, M.R., ESCHE, C., PERON, J.M., and LOTZE, M.T. (1997). Antitumor activities of IL-12 and mechanisms of action. Chem. Immunol. 68, 153-174.
44. SIDERS, W.M., WRIGHT, P.W., HIXON, J.A., ALVORD, W.G., BACK, T.C., WILTROUT, R.H., and FENTON, R.G. (1998). T cell-and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. J. Immunol. 160, 5465-5474.
45. SMYTH, M.J., GODFREY, D.I., and TRAPANI, J.A. (2001). A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2, 293-299.
46. SUMIMOTO, H., TANI, K., NAKAZAKI, Y., TANABE, T., HIBINO, H., WU, M.S., IZAWA, K., HAMADA, H., and ASANO, S. (1998). Superiority of interleukin-12- transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice. Cancer Gene Ther. 5, 29-37.
47. TAHARA, H., ZEH, H.J., 3RD, STORKUS, W.J., PAPPO, I., WATKINS, S.C., GUBLER, U., WOLF, S.F., ROBBINS, P.D., and LOTZE, M.T. (1994). Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54, 182-189.
48. TANNENBAUM, C.S., TUBBS, R., ARMSTRONG, D., FINKE, J.H., BUKOWSKI, R.M., and HAMILTON, T.A. (1998). The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161, 927-932.
49. TRINCHIERI, G. (1998). Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243.
50. WANG, L., QI, X., SUN, Y., LIANG, L., and JU, D. (2002). Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity. Cancer Gene Ther. 9, 819-824.
51. YASUDA, H., NAGATA, M., ARISAWA, K., YOSHIDA, R., FUJIHIRA, K., OKAMOTO, N., MORIYAMA, H., MIKI, M., SAITO, I., HAMADA, H., YOKONO, K., and KASUGA, M. (1998). Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. J. Clin. Invest. 102, 1807-1814.
52. YOSHIMOTO, T., WANG, C.R., YONETO, T., WAKI, S., SUNAGA, S., KOMAGATA, Y., MITSUYAMA, M., MIYAZAKI, J., and NARIUCHI, H. (1998). Reduced T helper 1 responses in IL-12 p40 transgenic mice. J. Immunol. 160, 588-594.
53. ZITVOGEL, L., TAHARA, H., ROBBINS, P.D., STORKUS, W.J., CLARKE, M.R., NALESNIK, M.A., and LOTZE, M.T. (1995). Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155, 1393-1403.